• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(11)C-胆碱 PET/CT 与增强 CT 在肺癌肺部异常和局部区域淋巴结受累患者评估中的比较。

Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer.

机构信息

Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong Province, China.

出版信息

Clin Lung Cancer. 2012 Jul;13(4):312-20. doi: 10.1016/j.cllc.2011.09.005. Epub 2011 Dec 17.

DOI:10.1016/j.cllc.2011.09.005
PMID:22182444
Abstract

UNLABELLED

Carbon-11 ((11)C)-choline positron emission tomography/computed tomography (PET/CT) is a new diagnostic method for detecting lung cancer. To prove whether it is superior to enhanced CT, we compared the diagnostic efficacy of these 2 approaches in 108 patients with pulmonary lesions and drew the conclusion that (11)C-choline PET/CT is not better at diagnosing primary lesions but is better at lymph node staging. This helps us to fully understand (11)C-choline PET/CT.

BACKGROUND

This study compares the diagnostic abilities of integrated (11)C-choline PET/CT imaging and contrast-enhanced helical CT imaging in pulmonary lesions and locoregional lymph node metastases in patients with lung cancer.

PATIENTS AND METHODS

One hundred eight patients with proven or suspected lung cancer underwent integrated (11)C-choline PET/CT and contrast-enhanced CT, followed by surgical resection and nodal staging.

RESULTS

The (11)C-choline PET/CT and CT diagnoses of pulmonary lesions and locoregional lymph node metastases were compared with pathologic findings, which revealed benign lesions in 26 patients (tuberculoma [8 patients], inflammatory pseudotumor [7 patients], hamartoma [6 patients], sclerosing hemangioma [4 patients], and pulmonary sequestration [1 patient]) and lung cancers in 82 patients (adenocarcinoma [39 patients], squamous cell carcinoma [23 patients], carcinoid [7 patients], small-cell lung cancer [5 patients], adenosquamous carcinoma [5 patients], and large-cell lung cancer [3 patients]). The accuracy, sensitivity, and specificity of (11)C-choline PET/CT for diagnosing lung cancer were 82.4%, 85.4%, and 73.1%, respectively, compared with 73.1%, 76.8%, and 61.5%, respectively, for CT. Differences between (11)C-choline PET/CT and CT in diagnosing lung cancer were not statistically significant (p = .503, .118, and .375, respectively). We used receiver operating characteristic (ROC) curve for analysis, finding the ROC of standard uptake value (SUV(max)) for diagnosing lung cancer. The cutoff value of SUV(max) was 3.54. Preoperative nodal staging was compared with postoperative histopathologic staging. (11)C-choline PET/CT correctly staged 80.5% of patients, 12.2% were overstaged, and 7.3% were understaged; for CT these values were 58.5%, 24.4%, and 17.1%, respectively. The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of (11)C-choline PET/CT for lymph nodes were 83.8%, 82.4%, 84.1%, 50.3%, and 96.1%, respectively, compared with 69.3%, 63.7%, 71.2%, 30.2%, 91.0%, respectively, for CT.

CONCLUSION

Differences in the accuracy, sensitivity, specificity, PPV, and NPV between (11)C-choline PET/CT and CT are thus statistically significant for nodal staging (p = .003, .007, .000, .000, and .004, respectively). Although (11)C-choline PET/CT is not significantly better at diagnosing pulmonary lesions than is enhanced CT, (11)C-choline PET/CT has improved sensitivity, specificity, accuracy, PPV, and NPV relative to enhanced CT in the evaluation of locoregional lymph nodes.

摘要

未注明

¹¹C-胆碱正电子发射断层扫描/计算机断层扫描(PET/CT)是一种用于检测肺癌的新诊断方法。为了证明它是否优于增强 CT,我们比较了这两种方法在 108 例肺部病变患者中的诊断效果,并得出¹¹C-胆碱 PET/CT 诊断原发性病变并不优于增强 CT,但淋巴结分期更好的结论。这有助于我们全面了解¹¹C-胆碱 PET/CT。

背景

本研究比较了¹¹C-胆碱 PET/CT 与增强螺旋 CT 在肺癌患者肺部病变和局部淋巴结转移中的诊断能力。

患者和方法

108 例经证实或疑似肺癌患者接受了¹¹C-胆碱 PET/CT 和增强 CT 检查,随后进行了手术切除和淋巴结分期。

结果

¹¹C-胆碱 PET/CT 和 CT 对肺部病变和局部淋巴结转移的诊断结果与病理结果进行了比较,其中 26 例患者为良性病变(结核瘤[8 例]、炎性假瘤[7 例]、错构瘤[6 例]、硬化性血管瘤[4 例]和肺隔离症[1 例]),82 例患者为肺癌(腺癌[39 例]、鳞状细胞癌[23 例]、类癌[7 例]、小细胞肺癌[5 例]、腺鳞癌[5 例]、大细胞肺癌[3 例])。¹¹C-胆碱 PET/CT 诊断肺癌的准确性、敏感性和特异性分别为 82.4%、85.4%和 73.1%,而 CT 分别为 73.1%、76.8%和 61.5%。¹¹C-胆碱 PET/CT 和 CT 诊断肺癌的差异无统计学意义(p =.503,.118,.375)。我们使用了接收器工作特征(ROC)曲线进行分析,得出了用于诊断肺癌的标准摄取值(SUV(max))的 ROC。SUV(max)的截断值为 3.54。术前淋巴结分期与术后组织病理学分期进行了比较。¹¹C-胆碱 PET/CT 正确分期 80.5%的患者,12.2%的患者分期过高,7.3%的患者分期过低;CT 分别为 58.5%、24.4%和 17.1%。¹¹C-胆碱 PET/CT 对淋巴结的准确性、敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)分别为 83.8%、82.4%、84.1%、50.3%和 96.1%,而 CT 分别为 69.3%、63.7%、71.2%、30.2%、91.0%。

结论

¹¹C-胆碱 PET/CT 与 CT 在淋巴结分期方面的准确性、敏感性、特异性、PPV 和 NPV 差异具有统计学意义(p =.003,.007,.000,.000,和.004)。尽管¹¹C-胆碱 PET/CT 在诊断肺部病变方面并不优于增强 CT,但¹¹C-胆碱 PET/CT 在评价局部淋巴结方面具有更高的敏感性、特异性、准确性、PPV 和 NPV。

相似文献

1
Comparison of (11)C-choline PET/CT and enhanced CT in the evaluation of patients with pulmonary abnormalities and locoregional lymph node involvement in lung cancer.(11)C-胆碱 PET/CT 与增强 CT 在肺癌肺部异常和局部区域淋巴结受累患者评估中的比较。
Clin Lung Cancer. 2012 Jul;13(4):312-20. doi: 10.1016/j.cllc.2011.09.005. Epub 2011 Dec 17.
2
Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy.[11C]胆碱正电子发射断层扫描/计算机断层扫描与常规计算机断层扫描在膀胱癌根治性膀胱切除术前淋巴结分期中的诊断效能比较。
Eur Urol. 2012 May;61(5):1031-8. doi: 10.1016/j.eururo.2011.12.009. Epub 2011 Dec 14.
3
Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer.PET/CT与增强CT对非小细胞肺癌局部区域淋巴结的诊断价值比较
Lung Cancer. 2008 Jul;61(1):35-43. doi: 10.1016/j.lungcan.2007.11.007. Epub 2008 Jan 4.
4
[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.18F 氟甲基胆碱(FCH)正电子发射断层扫描/计算机断层扫描(PET/CT)用于前列腺癌淋巴结分期:210 例患者的前瞻性研究。
BJU Int. 2012 Dec;110(11):1666-71. doi: 10.1111/j.1464-410X.2012.11150.x. Epub 2012 Apr 23.
5
The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.在肺部炎症性疾病患病率较高的地区,18F-氟脱氧葡萄糖正电子发射断层显像(FDG PET)成像在非小细胞肺癌术前分期中区分N0或N1期与N2期的附加价值。
Clin Nucl Med. 2007 Aug;32(8):607-12. doi: 10.1097/RLU.0b013e3180a1ac87.
6
Is mediastinoscopy still the gold standard to evaluate mediastinal lymph nodes in patients with non-small cell lung carcinoma?对于非小细胞肺癌患者,纵隔镜检查仍是评估纵隔淋巴结的金标准吗?
Thorac Cardiovasc Surg. 2012 Mar;60(2):116-21. doi: 10.1055/s-0030-1271148. Epub 2011 Jun 20.
7
Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings.(11)C-胆碱 PET/CT 在膀胱癌术前淋巴结分期中的诊断准确性:与增强 CT 和组织学检查的系统比较。
Clin Nucl Med. 2014 May;39(5):e308-12. doi: 10.1097/RLU.0000000000000342.
8
Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?在口腔/头颈部癌患者颈淋巴结病的诊断中,3'-脱氧-3'-(¹⁸F)氟胸苷的表现能优于2-脱氧-2-(¹⁸F)氟-D-葡萄糖正电子发射断层扫描/计算机断层扫描吗?
J Oral Maxillofac Surg. 2015 Jul;73(7):1420-8. doi: 10.1016/j.joms.2015.01.002. Epub 2015 Jan 13.
9
Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.一项针对淋巴结受累高危前列腺癌患者进行淋巴结分期功能成像的前瞻性试验的最终分析。
Urol Oncol. 2015 Mar;33(3):109.e23-31. doi: 10.1016/j.urolonc.2014.11.008. Epub 2015 Feb 2.
10
Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells.11C-胆碱 PET/CT 对肺癌诊断的价值及胆碱代谢与癌细胞增殖的关系。
Oncol Rep. 2013 Jan;29(1):205-11. doi: 10.3892/or.2012.2099. Epub 2012 Oct 23.

引用本文的文献

1
[Research Progress on Tumor Metabolic Biomarkers in Liquid Biopsy of Lung Cancer].[肺癌液体活检中肿瘤代谢生物标志物的研究进展]
Zhongguo Fei Ai Za Zhi. 2024 Feb 20;27(2):126-132. doi: 10.3779/j.issn.1009-3419.2023.106.29.
2
A nomogram for predicting the risk of lymph node metastasis in T1-2 non-small-cell lung cancer based on PET/CT and clinical characteristics.基于PET/CT和临床特征预测T1-2期非小细胞肺癌淋巴结转移风险的列线图
Transl Lung Cancer Res. 2021 Jan;10(1):430-438. doi: 10.21037/tlcr-20-1026.
3
Development of a nomogram for preoperative prediction of lymph node metastasis in non-small cell lung cancer: a SEER-based study.
非小细胞肺癌术前预测淋巴结转移列线图的开发:一项基于监测、流行病学和最终结果(SEER)数据库的研究
J Thorac Dis. 2020 Jul;12(7):3651-3662. doi: 10.21037/jtd-20-601.
4
LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling.长链非编码 RNA GMDS-AS1 通过调控 miR-96-5p/CYLD 信号通路抑制肺腺癌的发展。
Cancer Med. 2020 Feb;9(3):1196-1208. doi: 10.1002/cam4.2776. Epub 2019 Dec 20.
5
Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report and review of the literature.18氟胆碱PET/CT检测出的不明原发神经内分泌肿瘤(NET)的成骨性骨转移及其与68镓- DOTATOC PET/CT的比较:病例报告及文献复习
Medicine (Baltimore). 2017 Nov;96(46):e8567. doi: 10.1097/MD.0000000000008567.